MicroRNA‑140 suppresses Helicobacter pylori‑positive gastric cancer growth by enhancing the antitumor immune response

Zhao, Min; Liu, Qian; Liu, Wenxiang; Zhou, He; Zang, Xuan; Lu, Jie

doi:10.3892/mmr.2019.10475

Cited by 11 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the miR-140 overexpression-induced alterations were down-regulated by PD-L1 plasmid. These findings verified that miR140 exerts an anti-GC effect by targeting PD-L1 (48).…”

Section: Suppress-mirnassupporting

confidence: 75%

Molecular biology and immunology of gastric cancer peritoneal metastasis

Yao¹,

Ajani²,

Song³

2020

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.

show abstract

“…In addition, the miR-140 overexpression-induced alterations were down-regulated by PD-L1 plasmid. These findings verified that miR140 exerts an anti-GC effect by targeting PD-L1 (48).…”

Section: Suppress-mirnassupporting

confidence: 75%

Molecular biology and immunology of gastric cancer peritoneal metastasis

Yao¹,

Ajani²,

Song³

2020

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

“…MiR-140 played a suppressive role in the growth of gastric cancer in vitro and in vivo ( 54 , 55 ). It also strengthened antitumor immunity in gastric cancer ( 20 ). PD-L1 was directly targeted by miR-140 in gastric cancer cells ( 20 ).…”

Section: The Impact Of Ncrnas Targeting Pd-1/pd-l1 On Cancermentioning

confidence: 99%

The Role of NcRNAs to Regulate Immune Checkpoints in Cancer

Jiang

Zhao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

At present, the incidence of cancer is becoming more and more common, but its treatment has always been a problem. Although a small number of cancers can be treated, the recurrence rates are generally high and cannot be completely cured. At present, conventional cancer therapies mainly include chemotherapy and radiotherapy, which are the first-line therapies for most cancer patients, but there are palliatives. Approaches to cancer treatment are not as fast as cancer development. The current cancer treatments have not been effective in stopping the development of cancer, and cancer treatment needs to be imported into new strategies. Non-coding RNAs (ncRNAs) is a hot research topic at present. NcRNAs, which include microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs), participate in all aspects of cancer biology. They are involved in the progression of tumors into a new form, including B-cell lymphoma, glioma, or the parenchymal tumors such as gastric cancer and colon cancer, among others. NcRNAs target various immune checkpoints to affect tumor proliferation, differentiation, and development. This might represent a new strategy for cancer treatment.

show abstract

“…These findings suggest that miR-140 has an anti-GC effect by targeting the immunoassay molecule PD-L1. Therefore, miR-140 may be a promising and new immunotherapy target for GC treatment [ 146 ].…”

Section: Therapymentioning

confidence: 99%

Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer

et al. 2022

View full text Add to dashboard Cite

Metabolic disorders and abnormal immune function changes occur in tumor tissues and cells to varying degrees. There is increasing evidence that reprogrammed energy metabolism contributes to the development of tumor suppressive immune microenvironment and influences the course of gastric cancer (GC). Current studies have found that tumor microenvironment (TME) also has important clinicopathological significance in predicting prognosis and therapeutic efficacy. Novel approaches targeting TME therapy, such as immune checkpoint blockade (ICB), metabolic inhibitors and key enzymes of immune metabolism, have been involved in the treatment of GC. However, the interaction between GC cells metabolism and immune metabolism and how to make better use of these immunotherapy methods in the complex TME in GC are still being explored. Here, we discuss how metabolic reprogramming of GC cells and immune cells involved in GC immune responses modulate anti-tumor immune responses, as well as the effects of gastrointestinal flora in TME and GC. It is also proposed how to enhance anti-tumor immune response by understanding the targeted metabolism of these metabolic reprogramming to provide direction for the treatment and prognosis of GC.

show abstract

MicroRNA‑140 suppresses Helicobacter pylori‑positive gastric cancer growth by enhancing the antitumor immune response

Cited by 11 publications

References 38 publications

Molecular biology and immunology of gastric cancer peritoneal metastasis

Molecular biology and immunology of gastric cancer peritoneal metastasis

The Role of NcRNAs to Regulate Immune Checkpoints in Cancer

Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer

Contact Info

Product

Resources

About